This is a prospective, correlational, descriptive study on the effect of Recombinant Human Erythropoietin on the Quality of life (QOL) of hemodialysis patients in Iloilo Doctors Hospital Renal Care Unit, Iloilo City. The study is about the socio-demographic, clinical and laboratory profile and QOL assessment using twomeasures—Karnofsky Performance Status Scale (KPSS) and Medical Outcomes Short Form Health Survey (SF- 36). Baseline values were initially taken, after which, patientswere given their recombinant human erythropoietin dose for four weeks, based on their baseline hemoglobin levels, the duration of their treatment with recombinant humanerythropoietin and their weight. There were a total of 36 patients who came in at the Iloilo Doctors Hospital Renal Care Unit who were enrolled in the study. The data weredrawn using the Karnofsky Performance Status Scale (KPSS) and the Medical OutcomesShort Form Health Survey (SF 36), a multipurpose, short form health survey with 36 questions which was created by the International Quality of Life Assessment (IQOLA) Project and was documented by nearly 4,000 studies in terms of reliability and validity.The results showed that there is an improvement in hemoglobin, creatinine clearanceand serum albumin kevels after 4 weeks of recombinant human erythropoietin treatment.There is also an improvement in physical functioning, bodily pain handling,vitality, social functioning and role emotional; however there is no effect on the physical, general health and mental health after RHuEPO. There is also an improvement in Karnofsky scores after RHuEPO. Hemoglobin is an independent factor in physical functioning. The KPSS and the SF 36 survey has a positive correlation thus the former can be a good choice in patents who are not fully conscious and who cannot answer questions of the SF-36. Bodily pain and physical functioning also affects Karnofsky scoring.Thus this study recommends that further studies should be done regarding the factor which greatly affects physical functioning. Compliance to recombinant humanerythropoietin is needed. Every hemodialysis unit should be provided with counselors, psychiatrists or psychologists. Quality of life should be routinely done in everyhemodialysis at intervals of 3, 6 or 9 months to see whether the patient improves or deteriorates so that solutions can be done. The Karnofsky Performance Status Scale should take the place of SF-36 in patients who cannot converse or are not fullyconscious. Physical Functioning and Bodily pain scores should be elevated in order tomaintain a high KPSS score for QOL.